MX2019011003A - Mutaciones de empalmosoma y usos de las mismas. - Google Patents

Mutaciones de empalmosoma y usos de las mismas.

Info

Publication number
MX2019011003A
MX2019011003A MX2019011003A MX2019011003A MX2019011003A MX 2019011003 A MX2019011003 A MX 2019011003A MX 2019011003 A MX2019011003 A MX 2019011003A MX 2019011003 A MX2019011003 A MX 2019011003A MX 2019011003 A MX2019011003 A MX 2019011003A
Authority
MX
Mexico
Prior art keywords
mutations
spliceosome
methods
treatment
spliceosome mutations
Prior art date
Application number
MX2019011003A
Other languages
English (en)
Inventor
Zhu Ping
Puyang Xiaoling
Warmuth Markus
Teng Teng
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2019011003A publication Critical patent/MX2019011003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen aquí mutaciones del empalmosoma que incluyen mutaciones en las subunidades PHF5A Y SF3B1. Esta solicitud también describe la detección de la presencia y/o ausencia de mutaciones en el empalmosoma, y también métodos de diagnóstico de la responsividad al tratamiento con modulador de empalme, métodos de tratamiento de trastornos neoplásicos y métodos de monitoreo o alteración de tratamiento, basados en el estado de las mutaciones.
MX2019011003A 2017-03-15 2018-03-14 Mutaciones de empalmosoma y usos de las mismas. MX2019011003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471903P 2017-03-15 2017-03-15
PCT/US2018/022437 WO2018170129A1 (en) 2017-03-15 2018-03-14 Spliceosome mutations and uses thereof

Publications (1)

Publication Number Publication Date
MX2019011003A true MX2019011003A (es) 2019-12-16

Family

ID=61868877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011003A MX2019011003A (es) 2017-03-15 2018-03-14 Mutaciones de empalmosoma y usos de las mismas.

Country Status (13)

Country Link
US (1) US20200190593A1 (es)
EP (1) EP3596235A1 (es)
JP (1) JP2020514348A (es)
KR (1) KR20190137810A (es)
CN (1) CN110914457A (es)
AU (1) AU2018235940A1 (es)
BR (1) BR112019019092A2 (es)
CA (1) CA3056389A1 (es)
IL (1) IL268932A (es)
MX (1) MX2019011003A (es)
RU (1) RU2019132208A (es)
SG (1) SG11201907887SA (es)
WO (1) WO2018170129A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102419VA (en) 2018-12-13 2021-04-29 Eisai R&D Man Co Ltd Herboxidiene splicing modulator antibody-drug conjugates and methods of use
CN113384703B (zh) * 2021-06-21 2023-03-10 深圳市第二人民医院(深圳市转化医学研究院) Dhx34基因的表达抑制剂在制备抑制肝癌细胞转移和侵袭的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU703922B2 (en) 1995-12-28 1999-04-01 Kyowa Hakko Kogyo Co. Ltd. Compound gexi
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
CA2494536C (en) 2002-07-31 2011-10-04 Mercian Corporation A 12-membered ring macrolide active substance
JP4459051B2 (ja) 2002-07-31 2010-04-28 メルシャン株式会社 新規生理活性物質
BR0316746A (pt) 2002-11-29 2005-10-18 Mercian Corp Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550)
CN1886505A (zh) 2003-11-27 2006-12-27 美露香株式会社 参与大环内酯类化合物的羟化作用的dna
US8008049B2 (en) 2004-07-20 2011-08-30 Eisai R&D Management Co., Ltd. DNA coding for polypeptide participating in biosynthesis of pladienolide
JPWO2007043621A1 (ja) 2005-10-13 2009-04-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 プラジエノライドｂ及びプラジエノライドｄの全合成方法
WO2008009002A2 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
WO2008082730A2 (en) * 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
WO2013086464A1 (en) * 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
US20150025017A1 (en) * 2012-02-28 2015-01-22 Fred Hutchinson Cancer Research Center Compositions and methods for treating cancer
CN105121421B (zh) 2012-11-05 2020-10-02 辉瑞公司 司普力西欧他汀类似物
LT3143016T (lt) 2014-05-15 2019-06-10 Eisai R&D Management Co., Ltd. Pladienolido piridino junginiai ir panaudojimo būdai
JP6876680B2 (ja) * 2015-09-01 2021-05-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント

Also Published As

Publication number Publication date
EP3596235A1 (en) 2020-01-22
IL268932A (en) 2019-10-31
SG11201907887SA (en) 2019-09-27
RU2019132208A3 (es) 2021-04-15
BR112019019092A2 (pt) 2020-06-30
CN110914457A (zh) 2020-03-24
RU2019132208A (ru) 2021-04-15
JP2020514348A (ja) 2020-05-21
AU2018235940A1 (en) 2019-10-17
KR20190137810A (ko) 2019-12-11
US20200190593A1 (en) 2020-06-18
WO2018170129A1 (en) 2018-09-20
CA3056389A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
PH12019501095A1 (en) (aza)indole-,benzothiopene-, and benzofuran-3-sulfonamides
ZA201803366B (en) Antibody molecules to april and uses thereof
EP3685286C0 (en) EMAIL-BASED AUTHENTICATION FOR ACCOUNT LOGIN, ACCOUNT CREATION, AND SECURITY FOR PASSWORDLESS TRANSACTIONS
BR112017006664A2 (pt) terapias de combinação
CY1121529T1 (el) Σηματοδοτηση slit-robo για διαγνωση και θεραπεια νεφρικης νοσου
BR112018070133A2 (pt) dispersão, uso desta e método para a inativação fotodinâmica de micro-organismos
EP3532891A4 (en) DEVICES, SYSTEMS AND / OR METHODS FOR CONTROLLING SHORT-VISION
TN2017000129A1 (en) Antibody molecules to pd-l1 and uses thereof
MX383652B (es) Moduladores de la vía de estrés integrada.
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
MY187246A (en) Antibody molecules to lag-3 and uses thereof
MX2018012476A (es) Sistemas y metodos para determinar falla de dispositivos intragastricos.
BR112019003172A2 (pt) frações de plasma sanguíneo como tratamento para distúrbios cognitivos associados ao envelhecimento
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
MX376201B (es) Compuestos inhibidores de metaloenzima.
MY205689A (en) Antibody molecules to cd138 and uses thereof
MX395572B (es) Anticuerpos anti-htra1 y metodos de uso de los mismos
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
BR112018006986A2 (pt) métodos e composições para contrações musculares indesejadas ou anormais
WO2016040824A3 (en) METHODS OF IDENTIFYING MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USE OF SAME TO MODULATE mTORC1
EP4487912A3 (en) Improved treatment of atopic dermatitis with tradipitant
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.